Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum.

Creed RB, Menalled L, Casey B, Dave KD, Janssens HB, Veinbergs I, van der Hart M, Rassoulpour A, Goldberg MS.

Neuroscience. 2019 Jun 15;409:169-179. doi: 10.1016/j.neuroscience.2019.04.033. Epub 2019 Apr 25.

2.

A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.

Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM; The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group.

J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471.

3.

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4).

Chahine LM, Beach TG, Seedorff N, Caspell-Garcia C, Coffey CS, Brumm M, Adler CH, Serrano GE, Linder C, Mosovsky S, Foroud T, Riss H, Ecklund D, Seibyl J, Jennings D, Arnedo V, Riley L, Dave KD, Mollenhauer B; Systemic sSynuclein Sampling study.

J Parkinsons Dis. 2018;8(4):517-527. doi: 10.3233/JPD-181434.

4.

Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.

Mollenhauer B, Bowman FD, Drake D, Duong J, Blennow K, El-Agnaf O, Shaw LM, Masucci J, Taylor P, Umek RM, Dunty JM, Smith CL, Stoops E, Vanderstichele H, Schmid AW, Moniatte M, Zhang J, Kruse N, Lashuel HA, Teunissen C, Schubert T, Dave KD, Hutten SJ, Zetterberg H.

J Neurochem. 2019 Apr;149(1):126-138. doi: 10.1111/jnc.14569. Epub 2018 Nov 13.

5.

Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4).

Beach TG, Serrano GE, Kremer T, Canamero M, Dziadek S, Sade H, Derkinderen P, Corbillé AG, Letournel F, Munoz DG, White CL 3rd, Schneider J, Crary JF, Sue LI, Adler CH, Glass MJ, Intorcia AJ, Walker JE, Foroud T, Coffey CS, Ecklund D, Riss H, Goßmann J, König F, Kopil CM, Arnedo V, Riley L, Linder C, Dave KD, Jennings D, Seibyl J, Mollenhauer B, Chahine L; Systemic Synuclein Sampling Study (S4).

J Neuropathol Exp Neurol. 2018 Sep 1;77(9):793-802. doi: 10.1093/jnen/nly056.

6.

Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents.

Polinski NK, Volpicelli-Daley LA, Sortwell CE, Luk KC, Cremades N, Gottler LM, Froula J, Duffy MF, Lee VMY, Martinez TN, Dave KD.

J Parkinsons Dis. 2018;8(2):303-322. doi: 10.3233/JPD-171248.

7.

Therapeutic approaches to target alpha-synuclein pathology.

Brundin P, Dave KD, Kordower JH.

Exp Neurol. 2017 Dec;298(Pt B):225-235. doi: 10.1016/j.expneurol.2017.10.003. Epub 2017 Oct 4. Review.

8.

The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease.

Visanji NP, Mollenhauer B, Beach TG, Adler CH, Coffey CS, Kopil CM, Dave KD, Foroud T, Chahine L, Jennings D; Systemic Synuclein Sampling Study (S4).

Biomark Med. 2017 Apr;11(4):359-368. doi: 10.2217/bmm-2016-0366. Epub 2017 Mar 29.

9.

The hTH-GFP reporter rat model for the study of Parkinson's disease.

Iacovitti L, Wei X, Cai J, Kostuk EW, Lin R, Gorodinsky A, Roman P, Kusek G, Das SS, Dufour A, Martinez TN, Dave KD.

PLoS One. 2014 Dec 2;9(12):e113151. doi: 10.1371/journal.pone.0113151. eCollection 2014.

10.

Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease.

Dave KD, De Silva S, Sheth NP, Ramboz S, Beck MJ, Quang C, Switzer RC 3rd, Ahmad SO, Sunkin SM, Walker D, Cui X, Fisher DA, McCoy AM, Gamber K, Ding X, Goldberg MS, Benkovic SA, Haupt M, Baptista MA, Fiske BK, Sherer TB, Frasier MA.

Neurobiol Dis. 2014 Oct;70:190-203. doi: 10.1016/j.nbd.2014.06.009. Epub 2014 Jun 24.

11.

Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs.

Baptista MA, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, Varsho JS, Parker GA, Moore C, Churchill MJ, Meshul CK, Fiske BK.

PLoS One. 2013 Nov 14;8(11):e80705. doi: 10.1371/journal.pone.0080705. eCollection 2013.

12.

α-synuclein imaging: a critical need for Parkinson's disease research.

Eberling JL, Dave KD, Frasier MA.

J Parkinsons Dis. 2013;3(4):565-7. doi: 10.3233/JPD-130247.

PMID:
24192754
13.

A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research.

Baptista MA, Dave KD, Sheth NP, De Silva SN, Carlson KM, Aziz YN, Fiske BK, Sherer TB, Frasier MA.

Dis Model Mech. 2013 Nov;6(6):1316-24. doi: 10.1242/dmm.011940. Epub 2013 Sep 12.

14.

Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD).

Schindler EA, Dave KD, Smolock EM, Aloyo VJ, Harvey JA.

Pharmacol Biochem Behav. 2012 Mar;101(1):69-76. doi: 10.1016/j.pbb.2011.12.002. Epub 2011 Dec 14.

15.

Intrahippocampal LSD accelerates learning and desensitizes the 5-HT(2A) receptor in the rabbit, Romano et al.

Romano AG, Quinn JL, Li L, Dave KD, Schindler EA, Aloyo VJ, Harvey JA.

Psychopharmacology (Berl). 2010 Oct;212(3):441-8. doi: 10.1007/s00213-010-2004-7. Epub 2010 Sep 9.

PMID:
20827462
16.
17.
18.

Effect of serotonin depletion on 5-HT2A-mediated learning in the rabbit: evidence for constitutive activity of the 5-HT2A receptor in vivo.

Romano AG, Quinn JL, Liu R, Dave KD, Schwab D, Alexander G, Aloyo VJ, Harvey JA.

Psychopharmacology (Berl). 2006 Jan;184(2):173-81. Epub 2005 Dec 21.

PMID:
16369834
19.

A 5-HT2C agonist elicits hyperactivity and oral dyskinesia with hypophagia in rabbits.

Simansky KJ, Dave KD, Inemer BR, Nicklous DM, Padron JM, Aloyo VJ, Romano AG.

Physiol Behav. 2004 Aug;82(1):97-107.

PMID:
15234597
20.

Serotonin 5-HT2A receptors in the CA1 field of the hippocampus mediate head movements in the rabbit.

Dave KD, Fernando GS, Quinn JL, Harvey JA, Aloyo VJ.

Psychopharmacology (Berl). 2004 Nov;176(3-4):287-95. Epub 2004 Apr 24.

PMID:
15107968
21.

Role of central 5-HT2 receptors in mediating head bobs and body shakes in the rabbit.

Dave KD, Quinn JL, Harvey JA, Aloyo VJ.

Pharmacol Biochem Behav. 2004 Mar;77(3):623-9.

PMID:
15006475
22.

A novel behavioral model that discriminates between 5-HT2A and 5-HT2C receptor activation.

Dave KD, Harvey JA, Aloyo VJ.

Pharmacol Biochem Behav. 2002 May;72(1-2):371-8.

PMID:
11900808
23.

Selective and divergent regulation of cortical 5-HT(2A) receptors in rabbit.

Aloyo VJ, Dave KD, Rahman T, Harvey JA.

J Pharmacol Exp Ther. 2001 Dec;299(3):1066-72.

PMID:
11714896

Supplemental Content

Support Center